Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy
Start Date
4/19/2024
Completion Date
4/19/2030
Summary
The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.
Detailed Description
This aims to collect observational data that describe clinical (primary endpoint) and subclinical (secondary endpoint) cardiopulmonary toxicities from combined thoracic radiotherapy and immunotherapy up to 25 months after thoracic radiotherapy and 12 months after consolidation immunotherapy among patients with locally advanced lung cancer.
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
Curative Radiotherapy
Immunotherapy
Conditions
Locations
University of Missouri - Ellis Fischel Cancer Center
Columbia, Missouri 65212
United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey 08901
United States
University of Rochester Medical Center
Rochester, New York 14642
United States